Perioperative FOLFOX in Patients With Locally Advanced Oesogastric Adenocarcinoma.
Adenocarcinoma
/ blood
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
CA-19-9 Antigen
/ blood
Carcinoembryonic Antigen
/ blood
Disease-Free Survival
Docetaxel
/ administration & dosage
Esophagogastric Junction
/ drug effects
Female
Fluorouracil
/ administration & dosage
Humans
Leucovorin
/ administration & dosage
Male
Middle Aged
Neoadjuvant Therapy
Organoplatinum Compounds
/ administration & dosage
Oxaliplatin
/ administration & dosage
Perioperative Period
Proportional Hazards Models
Stomach Neoplasms
/ blood
Oesogastric adenocarcinoma
oxaliplatin
perioperative chemotherapy
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
05
11
2021
revised:
25
11
2021
accepted:
30
11
2021
entrez:
31
12
2021
pubmed:
1
1
2022
medline:
14
1
2022
Statut:
ppublish
Résumé
We hypothesized that perioperative FOLFOX (5-fluorouracil, leucovorin, oxaliplatin) might be used as an alternative to standard FLOT (docetaxel, 5-fluorouracil, leucovorin, and oxaliplatin) in patients with locally advanced oesogastric adenocarcinomas (OGA), particularly those with frailties. We reviewed the charts of 61 consecutives patients treated with FOLFOX for resectable OGA to estimate overall survival, recurrence-free survival, and safety. The median follow-up was 69.7 (range=3.6-97.9) months. Few patients experienced grade 3 adverse events during the preoperative (n=6; 10%) and postoperative (n=6; 16%) phases. One patient experienced a fatal grade 5 adverse events (cardiogenic shock). Median overall survival was 51.7 months [95% confidence interval (CI)=31.6-93.2 months] and the 5-year survival rate was 44.4% (95% CI=30.3%-57.5%). Regarding its comparable efficacy and its favourable toxicity profile, perioperative FOLFOX is a reasonable alternative to FLOT for frail patients with resectable OGA.
Sections du résumé
BACKGROUND
BACKGROUND
We hypothesized that perioperative FOLFOX (5-fluorouracil, leucovorin, oxaliplatin) might be used as an alternative to standard FLOT (docetaxel, 5-fluorouracil, leucovorin, and oxaliplatin) in patients with locally advanced oesogastric adenocarcinomas (OGA), particularly those with frailties.
PATIENTS AND METHODS
METHODS
We reviewed the charts of 61 consecutives patients treated with FOLFOX for resectable OGA to estimate overall survival, recurrence-free survival, and safety.
RESULTS
RESULTS
The median follow-up was 69.7 (range=3.6-97.9) months. Few patients experienced grade 3 adverse events during the preoperative (n=6; 10%) and postoperative (n=6; 16%) phases. One patient experienced a fatal grade 5 adverse events (cardiogenic shock). Median overall survival was 51.7 months [95% confidence interval (CI)=31.6-93.2 months] and the 5-year survival rate was 44.4% (95% CI=30.3%-57.5%).
CONCLUSION
CONCLUSIONS
Regarding its comparable efficacy and its favourable toxicity profile, perioperative FOLFOX is a reasonable alternative to FLOT for frail patients with resectable OGA.
Identifiants
pubmed: 34969724
pii: 42/1/185
doi: 10.21873/anticanres.15472
doi:
Substances chimiques
CA-19-9 Antigen
0
Carcinoembryonic Antigen
0
Organoplatinum Compounds
0
Oxaliplatin
04ZR38536J
Docetaxel
15H5577CQD
Leucovorin
Q573I9DVLP
Fluorouracil
U3P01618RT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
185-193Informations de copyright
Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.